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ABSTRACT 
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation, which if left untreated leads to progressive 
disability and joint destruction. A combination of anti-inflammatory agents, steroids, disease-modifying antirheumatic drugs (DMARDs), 
and biological agents are used to treat RA. Patients who fail to respond to traditional DMARDs may receive tumor necrosis factor-α (TNF-α) 
antagonists. However, approximately one-third of patients fail TNF-α antagonists due to adverse effects or lack of efficacy, and there are 
limited treatment options available to these patients. As knowledge of the underlying immunopathology of RA evolves, new strategies for 
inhibiting  the  inflammatory  process  have  emerged.  It  is  well  known  that  activated  T  cells  play  a  key  role  in  orchestrating  the 
immunopathological mechanisms of RA. Inhibiting the full activation of T cells is a rational strategy in the treatment of RA and represents a 
novel method of inhibiting disease activity, distinct from inflammatory cytokine blockade. Abatacept, a soluble human fusion protein that 
selectively modulates the co-stimulatory signal required for full T-cell activation, is approved for the treatment of rheumatoid arthritis (RA) 
in the United States, Canada, and the European Union. It is approved for reducing the signs and symptoms of RA, inducing major clinical 
response, slowing the progression of structural damage, and improving physical function in RA patients with moderate-to-severe disease who 
have had an inadequate response to other disease modifying, anti-rheumatic drugs (DMARDs) or tumor necrosis factor (TNF) antagonists. 
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INTRODUCTION 
Rheumatoid arthritis (RA) is the most common systemic 
inflammatory  autoimmune  disease  characterized  by 
symmetrical  joint  involvement.  RA  can  cause 
irreversible joint deformities and functional impairment. 
The estimated prevalence is 1% to 2%, and there is no 
racial  predilection
1.  The  disease  appears  to  be  two  to 
three times greater in women
2. Its onset is usually earlier 
in  women,  commonly  beginning  in  the  childbearing 
years
3.
 
Chronic  inflammation of the synovial tissue  lining the 
joint capsule results in the proliferation of this tissue and 
synovium-lining cells, resulting in synovial hyperplasia 
and vascularization. Inflammatory cells in the synovial 
tissue of patients with RA include macrophages, B and T 
lymphocytes and plasma cells. 
The  proinflammatory  cytokines-tumor  necrosis  factor 
(TNF), interleukin-1 (IL-1), and interleukin-6 (IL-6) are 
key  substances  in  the  initiation  and  continuation  of 
rheumatoid  inflammation
2.  Cytokine  release  in  the 
synovium is the result of CD4+ T cells being activated 
by  arthritogenic  antigens  associated  with  major 
histocompatibility complex (MHC) class II molecules on 
antigen-presenting cells (APCs)
4.
 
The symptoms of RA usually develop insidiously over 
the  course  of  several  weeks  to  months.  Prodromal 
symptoms  include  fatigue,  weakness,  low-grade  fever, 
loss  of  appetite  and  joint  pain.  Stiffness  and  muscle 
aches  may  precede  the  development  of  joint  swelling. 
The small joints of the hands, wrists, and feet are most 
commonly  affected  in  RA.  The  knee  can  also  be 
involved  with  loss  of  cartilage,  instability,  and  joint 
pain
1,5. Extra-articular involvement including rheumatoid 
nodules,  vasculitis,  eye  inflammation,  neurological 
dysfunction,  cardiopulmonary  disease, 
lymphadenopathy, and splenomegaly are manifestations 
of the disease
1,6.  
Traditional  pharmacological  therapies  for  RA  have 
included  nonsteroidal  anti-inflammatory  drugs 
(NSAIDs),  corticosteroids  and  disease-modifying 
antirheumatic drugs (DMARDs) such as gold salts, D-
penicillamine,  hydroxychloroquine,  azathioprine, 
cyclosporine,  sulfasalazine  and  methotrexate  (MTX). 
Recent advances in understanding the cytokine networks 
that  are  responsible  for  the  ongoing  inflammatory 
response in RA have led to the development of biological 
response modifiers (BRMs)
7,8.
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BRMs that have been approved for the treatment of RA 
include  adalimumab  (Humira®,  Abbott),  etanercept 
(Enbrel®,  Amgen/Wyeth)  and  infliximab  (Remicade®, 
Centocor) which are  inhibitors of TNF-α and anakinra 
(Kineret®, Amgen) which is a recombinant IL-1 receptor 
antagonist. 
Although  DMARDs  and  TNF-α  inhibitors  can  slow 
disease  progression  in  RA,  only  two-thirds  of  patients 
respond to therapy
9.
 Nearly seven years after infliximab 
was  introduced  on  the  market,  new  hope  is  finally 
emerging with the development of biological therapies. 
The  efficacy  of  these  agents  in  RA  has  been 
demonstrated in recently published randomized, placebo-
controlled trials involving a monoclonal antibody to the 
IL-6  receptor  (MRA),  a  monoclonal  B-cell  specific 
antibody  to  CD20  (rituximab  [Rituxan®, 
Biogen/Genentech])  and  a  cytotoxic  T-lymphocyte 
associated antigen 4 immunoglobulin (CTLA4-Ig), also 
called  abatacept.  Abatacept  (Orencia,  Bristol-Myers 
Squibb) is a fusion protein in a new class of drugs called 
the co-stimulation modulators
9,10.
 
THE  RATIONALE  FOR  MODULATING  T-
CELL  ACTIVATION  IN  RA 
RA is an auto inflammatory disease involving multiple 
cell  types  including  dendritic  cells,  macrophages, 
monocytes,  T  and  B  cells,  endothelial  cells  and 
fibroblasts which respond to genetic and environmental 
factors. Although the etiology of RA remains obscure, it 
is  thought  that  an  unknown  antigen  triggers  a  pro-
inflammatory  signaling  cascade  within  the  synovium.
 
Activated T cells play a central role in this pathway by 
initiating  this  cascade  with  subsequent  stimulation  of 
macrophages  and  synovial  fibroblasts  to  produce 
inflammatory  cytokines  including  TNF-α,  interleukin-2 
and interferon-γ
11. T cells are also involved in activating 
B  cells  which  then  produce  autoantibodies  such  as 
rheumatoid  factor  and  anti-cyclic  citrullinated 
peptides
12,13. In addition, activated T cells produce the 
receptor activator of nuclear  factor-κB (RANK)  ligand 
that in turn binds to RANK on osteoclasts. This induces 
bone  resorption  and  also  stimulates  chondrocytes  to 
produce  matrix  metalloproteinases-1  and  -3  leading  to 
cartilage destruction
14.
  
ABATACEPT:  A  SELECTIVE  T-CELL  CO-
STIMULATION MODULATOR 
Abatacept is a selective modulator of the CD80 or CD86 
signal which is required for full T-cell activation.  It is 
FDA approved for reducing the signs and symptoms of 
RA  to  slow  the  progression  of  structural  damage  and 
improving  physical  function  in  RA  patients  with 
moderate-to-severe disease who have had an inadequate 
response to other disease modifying anti-rheumatic drugs 
(DMARDs) or tumor necrosis factor (TNF) antagonists. 
By  targeting  T  cells,  abatacept  has  a  fundamentally 
different  mechanism  of  action  in  compare  to  other 
therapies for RA. Abatacept modulates T-cell activation 
by binding to CD80 and CD86 and 
thereby  blocking  interaction  with  CD28.  For  full 
activation, T cells require two distinct signals. The first 
occurring  when  major  histocompatibility  complex 
molecules on antigen-presenting cells (APCs)
 present a 
peptide  to  the  T-cell  receptor
15.  The  second  co-
stimulatory  signal  is  provided  by  further  interaction 
between specific receptors on the APC and the T cell. If 
only one of the signals is transmitted, full activation of T 
cells does not occur. Abatacept was developed to mimic 
the  action  of  an  endogenous  protein  and  cytotoxic  T-
lymphocyte-associated antigen-4 (CTLA-4).  CTLA-4 is 
a  transmembrane  protein  which  acts  as  a  negative 
regulator  of  T-cell  activation.  It  binds  to  CD80/CD86 
with  higher  affinity  than  CD28  and  thus  inhibit  the 
positive  co-stimulatory  signal.  Abatacept  is  a  fully 
soluble  human  fusion  protein,  incorporating  only  the 
extracellular domain of human CTLA-4, which is then 
linked  to  a  modified  Fc  portion  of  human 
immunoglobulin G1
16. The modified Fc region helps to 
stabilize  the  fusion  protein  but  is  not  therapeutically 
active.  So,  abatacept  does  not  mediate  complement-
dependent  cytotoxicity  or  antibody-dependent  cell-
mediated  cytotoxicity  (ADCC).  These  latter  effects 
(complement-dependent cytotoxicity and ADCC) lead to 
cell lysis, which has been linked to adverse events such 
as serious infusion reactions
17. In relation to its unique 
selectivity  of    modulating  T-cell  co-stimulation, 
abatacept results in decreased proinflammatory cytokine 
secretion  and  decreased  autoantibody  production
18, 
thereby  making  T-cell  co-stimulation  modulation  a 
rational strategy for RA therapy. 
PHARMACOLOGY 
Abatacept is a selective co stimulator modulator. It is a 
soluble  fusion  protein  which  contains  the  extracellular 
domain  of  human  cytotoxic  T-lymphocyte  associated 
antigen 4 (CTLA-4) which is linked to the modified Fc 
portion  of  human  immunoglobulin  G1.  In  unaltered 
disease, antigen-presenting cell proteins CD80 or CD86 
bind to the CD28 protein on T cells, thus facilitating T-
cell  activation  and  RA  disease  progression.  Abatacept 
competes  with  CD28  for  binding  to  CD80  and CD86. 
Abatacept’s greater affinity for CD80 and CD86 allows 
it to selectively modulate T-cell activation. The binding 
inhibits sustained T-cell proliferation and the production 
of proinflammatory cytokines
19. Here, abatacept inhibits 
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Radiographic  assessments  demonstrated  an  inhibitory 
effect  on  structural  damage  progression  at  Month  6, 
which was  maintained  for 6  months  following therapy 
cessation, with similar trends observed for MRI assessed 
osteitis, erosion and synovitis
20. 
PHARMACOKINETICS  
Healthy Adults and Adult RA 
The  pharmacokinetics  of  abatacept  was  studied  in 
healthy  adult  subjects  after  a  single  10  mg/kg 
intravenous infusion and in RA patients after multiple 10 
mg/kg  intravenous  infusions  (Table  1).  The 
pharmacokinetics  of  abatacept  in  RA  patients  and 
healthy  subjects  appeared  to  be  comparable.  In  RA 
patients,  after  multiple  intravenous  infusions,  the 
pharmacokinetics  of  abatacept  showed  proportional 
increases of Cmax and AUC over the dose range of 2 
mg/kg to 10 mg/kg. At 10 mg/kg, serum concentration 
appeared to reach a steady-state by day 60 with a mean 
(range) trough concentration of 24 (1 to 66) mcg/mL. No 
systemic  accumulation  of  abatacept  occurred  upon 
continued repeated treatment with 10 mg/kg at monthly 
intervals  in  RA  patients.  Population  pharmacokinetic 
analyses in RA patients revealed that there was a trend 
toward  higher  clearance  of  abatacept  with  increasing 
bodyweight. Age and gender (when corrected for body 
weight)  did  not  affect  clearance.  Concomitant 
methotrexate (MTX), NSAIDs, corticosteroids and TNF 
blocking  agents  did  not  influence  abatacept  clearance. 
No formal studies were conducted to examine the effects 
of  either  renal  or  hepatic  impairment  on  the 
pharmacokinetics of abatacept
21. 
Juvenile Idiopathic Arthritis 
In patients 6 to 17 years of age, the mean (range) steady-
state serum peak and trough concentrations of abatacept 
were 217 (57 to 700) and 11.9 (0.15 to 44.6) mcg/ml. 
Population  pharmacokinetic  analyses  of  the  serum 
concentration  data  showed  that  clearance  of  abatacept 
increased  with  baseline  body  weight.  The  estimated 
mean  (range)  clearance  of  abatacept  in  the  juvenile 
idiopathic  arthritis  patients  was  0.4  (0.20  to  1.12) 
ml/h/kg. After accounting for the effect of body weight, 
the  clearance  of  abatacept  was  not  related  to  age  and 
gender.  Concomitant  methotrexate,  corticosteroids  and 
NSAIDs  were  also  shown  not  to  influence  abatacept 
clearance
21. 
PRECLINICAL DEVELOPMENT 
The ability of abatacept to suppress deleterious immune 
responses  has  been  extensively  investigated  in  rodent 
models  of  transplant  rejection.  An  early  study 
demonstrated  that  abatacept  therapy  could  block 
rejection  of  human  pancreatic  islet  grafts  in  mice  by 
preventing  T-cell  recognition
22.  In  several  subsequent 
studies, abatacept prolonged the survival of diverse types 
of  vascularized  solid-organ  allografts  including  heart, 
kidney,  liver,  intestine  and  lung
23,24.
  No  toxicity  was 
observed in animal models. Abatacept was well tolerated 
in  nonhuman  primates  and  rodents  and  did  not  cause 
general  immunosuppression  or  alterations  in 
hematological parameters
22. However, as abatacept is a 
modulatorof  T-cell  function;  some  degree  of  systemic 
alteration is expected. 
CLINICAL DEVELOPMENT 
Phase 1 (Psoriasis) 
Abrams et al. 
A  multicenter,  open-label,  dose  escalation  study  was 
conducted  in  43  patients  with  moderate  to  severe 
psoriasis.  The  patients  received  four  intravenous 
infusions of abatacept on days 1, 3, 16, and 29 and were 
observed  for  up  to  26  weeks  after  treatment.  Overall, 
46% of the treated patients achieved greater than 50% 
improvement in disease activity, compared with baseline 
values;  only  4%  of  23  control  patients  achieved  this 
response
25. 
Abrams et al. 
Skin  biopsy  analyses  have  demonstrated  that  clinical 
improvement  was  associated  with  reduced  cellular 
activation  of  T  cells,  keratinocytes  and  vascular 
endothelium  in  the  psoriatic  lesions.  There  was  also  a 
reduction in CD80, CD86 and MHC class II expression 
of dendritic cells and a decrease in their numbers within 
the  psoriatic  lesions
26.  Although  abatacept  was  well 
tolerated 
in this study, there have been no reports  of its use in 
treating psoriasis since January 2003. 
Phase 2 (Rheumatoid Arthritis) 
Olle et al. 
In  a  double-blind,  placebo-controlled  pilot  trial, 
abatacept  was  administered  to  214  patients  with  RA 
whose  disease  had  not  been  controlled  with  standard 
DMARDs.  Patients  were  given  0.5,  2  or  10  mg/kg  of 
CTLA4-Ig as monotherapy. Infusions were administered 
on days 1, 15, 29 and 57. Patients were evaluated on day 
85, with a follow-up period extending to day 169. The 
primary efficacy endpoint was the proportion of patients 
meeting  the  American  College  of  Rheumatology  20% 
improvement  criteria  (ACR  20).  For  patients  who 
completed  the  study  to  day  85,  there  was  a  dose-
dependent  improvement  in  ACR  20  responses  after 
abatacept  treatment,  reaching  a  response  rate  of  23% 
with 0.5 mg/kg, 44% with 2 mg/kg, 53% with 10 mg/kg 
and  31%  with  placebo.  Abatacept  infusions  were  well 
tolerated at all dose levels. No notable renal, hepatic or 
hematological  adverse  drug  events  (ADEs)  were 
observed during the trial.  Overall, 173 of 214 patients Mehta Hiren R et al. IRJP 2 (7) 2011 34-39 
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(81%) reported ADEs during the treatment period and 
129 patients reported ADEs during the follow-up period 
(Table 2). Clinical and laboratory evaluation in this study 
generally  demonstrated  efficacy  for  abatacept  in  the 
treatment of signs and symptoms of RA
27. 
Kremer et al. 
A  double-blind,  randomized,  placebo  controlled 
investigation  of  the  effectiveness  of  abatacept  was 
performed  in  339  patients  with  RA  who  had  not 
responded  to  previous  MTX  therapy.  Patients  were 
randomly assigned to receive 10 mg/kg of abatacept, 2 
mg/kg  of  abatacept  or  placebo  on  days  1,  15,  30  and 
monthly thereafter for six months. All patients continued 
to receive a stable dose of MTX (10–30 mg/week) and, if 
required, a low dose of corticosteroids (10 mg/day) and 
NSAIDs.  After  six  months,  ACR  20  (20% 
improvement),  ACR  50  (50%  improvement)  and  ACR 
70  (70%  improvement)  responses  were  significantly 
higher  with  abatacept  10  mg/kg  than  with  placebo. 
Patients receiving abatacept 2 mg/kg did not demonstrate 
any  ACR 20 responses that differed significantly  from 
those taking placebo, but they did achieve significantly 
higher ACR 50 and ACR 70 responses
28. 
Weinblatt et al. 
Another study was conducted to evaluate the efficacy of 
abatacept in RA patients whose disease remained active 
despite  treatment  with  etanercept.  In  this  six-month, 
double-blind,  placebo-  controlled  trial,  all  patients 
continued to receive etanercept 25 mg twice weekly in 
addition to once-monthly infusions of either abatacept 2 
mg/kg or placebo. A total of 48.2% of patients receiving 
abatacept  achieved  ACR  20  responses,  compared  with 
27.8% receiving placebo. The addition of abatacept to 
etanercept also resulted in  improved quality of life for 
these patients
29. 
Phase 3 
Data from two large phase 3 studies of abatacept in RA 
were  presented  at  the  European  League  Against 
Rheumatism  (EULAR)  Congress  held  in  Vienna, 
Austria, in June 2005. 
Steinfeld et al. (AIM) 
The first study examined the individual components of 
the  ACR  criteria  over  time  in  RA  patients  in    AIM 
(Abatacept  in  Inadequate  responders  to  Methotrexate) 
trial. This one-year, randomized, double-blind, placebo-
controlled trial included 652 patients with an inadequate 
response to MTX. Patients were randomly assigned to 
receive  either placebo or a fixed dose of  abatacept 10 
mg/kg while continuing their MTX therapy. At one year, 
73.1%  of  these  patients  achieved  ACR  20  responses, 
48.3% achieved ACR 50 responses and 28.8% achieved 
ACR  70  responses  with  the  active  drug.  The 
corresponding rates for the placebo patients were 39.7%, 
18.2% and 6.1% respectively. Significant improvements 
were  also  observed  by  three  months  in  all  ACR 
components; these continued to increase through six and 
12  months  (Table  3).  Radiographic  evaluation  showed 
significant  reductions  in  the  progression  of  erosions, 
joint  space  narrowing  and  total  scores  with  abatacept 
compared  with  placebo  (Table  4).  Abatacept  was 
generally safe and well tolerated in this population
30.
 
Genovese et al. (ATTAIN) 
The  Abatacept  Trial  in  Treatment  of  Anti-TNF 
Inadequate Responders (ATTAIN) evaluated the efficacy 
and  safety  of  abatacept  for  a  period  of  six  months  in 
patients with active RA and an inadequate response to 
TNF inhibitors. The patients were randomly assigned to 
receive abatacept 10 mg/kg or placebo on days 1, 15, 29 
and every 28 days thereafter for six months in addition to 
at least one DMARD. Patients discontinued anti-TNF-α 
therapy  before  randomization.  After  six  months  of 
treatment,  50.4%  of  the  patients  receiving  abatacept 
achieved  ACR 20 responses, compared with 19.5% of 
the  patients  receiving  placebo.  In  addition,  20.3%  of 
patients  in  the  abatacept  group  achieved  ACR  50 
responses  and  10.2%  achieved  ACR  70  responses.  By 
contrast,  3.8% of  the  patients  taking  placebo  achieved 
ACR 50 responses and 1.5% reached ACR 70 responses. 
Remission rates were also measured; after 24 weeks of 
therapy, 10% of abatacept patients achieved remission, 
compared with 0.8% of those receiving placebo. In the 
ATTAIN  trial,  the  incidence  of  adverse  events  was 
similar  between  abatacept  and  placebo.  The  most 
common  adverse  reactions  were  headache  and 
nasopharyngitis
31. 
The  Cochrane  Review  meta-analysis  assessed  safety 
across the biologic DMARDs based on withdrawals from 
clinical trials due to AEs . Based on this criterion, there 
was  a  trend  towards  a  favourable  safety  profile  of 
abatacept  vs  placebo,  relative  to  adalimumab  or 
infliximab
32. 
ADVERSE EVENTS AND CONTRAINDICATIONS 
Abatacept treatment was not associated with any major 
adverse effects in the clinical trials. The most frequently 
reported  ADEs  included  headache,  upper  respiratory 
tract  infection,  musculoskeletal  pain,  nausea  and 
vomiting. These ADEs occurred at comparable rates in 
the  abatacept  and  placebo  groups
22,24.
  Clinically 
significant adverse complications of immunosuppression 
such as opportunistic infections and malignancy were not 
observed.  The  FDA  Advisory  Committee  plans  to 
consider the increased risk of infection when the drug is 
administered concomitantly with other anti-TNF agents. 
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risk for lung cancer. The number of overall malignancies 
has been “less than expected” in a healthy population; 
however, RA patients are known to have higher rates of 
malignancies than non-RA patients. There was a higher 
incidence  of  lung  cancer  and  lymphoma  than  the  rate 
expected
33. Abatacept has not been reported to lead to 
increased  formation  of  ANA  and  anti-ds  DNA 
antibodies, compared with placebo
34.  
CONCLUSION 
Abatacept is a fusion protein combining the extracellular 
portion of human CTLA-4 and IgG. It  has clearly been 
shown  to  be  effective  at  controlling  the  signs  and 
symptoms  of  RA,  particularly  at  a  dose  of  10  mg/kg 
given  monthly.  Selective  T-cell  co-stimulation 
modulation with abatacept offers a potentially valuable 
therapeutic  option  for  patients  with  RA  who  are 
refractory  to  TNF-α  antagonist  therapy  and  have 
progressed through the treatment paradigm and are more 
likely  to  have  severe  disease.    Clinical  trials  have  not 
shown an increase in ADEs compared with placebo. It is 
a  novel  drug  in  the  treatment  of  rheumatoid  arthritis, 
although  its cost and the  lack of experience with  long 
term  use  should  limit  its  use  to  patients  who  are 
refractory  to  or  have  had  serious  reactions  to  other 
treatments. Longer term data on efficacy and safety are 
needed  to  further  validate  T-cell  co-stimulation 
modulation as a therapeutic approach for RA. 
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TABLE 1: PHARMACOKINETIC PARAMETER (MEAN, RANGE) IN HEALTHY SUBJECTS AND RA PATIENTS AFTER 10 MG/KG INTRAVENOUS INFUSION(S) 
 
PK Parameter 
Healthy Subjects(After 10mg/kg Single 
Dose) 
n=13 
RA Pateints(After 10 mg/kg Multiple 
Doses
a) 
n=14 
Peak Concentration(Cmax) [mcg/ml]  292(175-427)  295(171-398) 
Terminal half life(t1/2) 
[days]  16.7(12-23)  13.1(8-25) 
Systemic  Clearnce (CL) 
[ml/h/kg]  0.23(0.16-0.30)  0.22(0.13-0.47) 
Volume of distribution(Vss) 
[L/kg] 
0.09(0.06-0.13)  0.07(0.02-0.13) 
a Multiple intravenous infusions were administered at days 1, 15, 30, and monthly thereafter 
 
TABLE 2: ADVERSE DRUG EVENTS OCCURRING UP TO DAY 85 AFTER ABATACEPT (CTLA4-IG) THERAPY FOR RHEUMATOID ARTHRITIS 
 
Event  Placebo  CTLA4-Ig 
Headache  1 (3.1%)  8 (8.9%) 
Nausea and vomiting  2(6.3%)  5 (5.6%) 
Fatigue  1 (3.1%)  4 (4.4%) 
Arthritis  3 (9.4%)  4 (4.4%) 
Hypotension  2 (6.3%)  3 (3.3%) 
 
 
TABLE 3: MEAN PERCENT IMPROVEMENT FROM BASELINE IN AMERICAN COLLEGE OF RADIOLOGY COMPONENTS AFTER ABATACEPT AND 
PLACEBO THERAPY FOR RHEUMATOID ARTHRITIS 
 
Duration  1 Month  3 Months  6 Months  12 Months 
  Abatacept  Placebo  Abatacept  Placebo  Abatacept  Placebo  Abatacept  Placebo 
Tender joints  31.9  25.4  52.8  34.9  62.6  40.7  68.8  42.1 
Swollen joints  33.5  27.2  54.7  33.2  65.0  39.5  70.5  42.4 
Pain  19.8 
  2.9  39.5  5.2  42.5  3.5  50.5  8.0 
Physical function  15.8  12.7  30.2  21.3  35.2  20.9  37.3  19.6 
Patient global  21.2 
  2.9  39.6  16.6  42.0  13.7  48.3  19.6 
Physician global  33.1  21.4  53.6  36.1  62.2  36.5  68.0  37.9 
 
 
 
TABLE 4: JOINT SPACE NARROWING SCORES AND TOTAL SCORES IN PLACEBO AND ABATACEPT PATIENTS WITH AN INADEQUATE RESPONSE TO 
METHOTREXATE (MTX) 
 
 
Change from baseline  Abatacept + MTX  Placebo + MTX 
Erosion score 
 
Mean (SD) Median 
(25th, 75th percentile) 
0.63 (1.77) 
0.00 (0.00, 1.02) 
1.14 (2.81) 
0.27 (0.00, 1.27) 
Joint space narrowing score  Mean (SD) Median 
(25th, 75th percentile) 
0.58 (1.54) 
0.00 (0.00, 0.49 
1.18 (2.58) 
0.00 (0.00, 0.97) 
Total score  Mean (SD) Median 
(25th, 75th percentile) 
1.21 (2.94)) 
0.25 (0.00, 1.78) 
2.32 (5.04) 
0.53 (0.00, 2.54) 
 
 
 
 
 
 
 
 